How Do Kesimpta and Ocrevus Compare Head-to-Head?
Kesimpta (ofatumumab) and Ocrevus (ocrelizumab) are both B-cell depleting monoclonal antibodies for relapsing multiple sclerosis (RMS) and active secondary progressive MS (SPMS). No head-to-head clinical trials directly compare them, so "better" depends on efficacy, safety, administration, and patient factors. Both reduce relapse rates by about 50-60% versus interferons or placebo in pivotal trials, with similar MRI lesion reductions.1
| Aspect | Kesimpta | Ocrevus |
|--------|----------|---------|
| Dosing | Monthly subcutaneous self-injection (20 mg after initial doses) | Every 6 months IV infusion (2 hours) |
| Efficacy in RMS | 50-59% relapse reduction (ASCLEPIOS trials, n=1,882) | 46-47% relapse reduction (OPERA trials, n=1,656) |
| SPMS Approval | No (RMS only) | Yes (active SPMS) |
| Onset of Action | Faster B-cell depletion (within 1 day) | Slower (peaks at 2 weeks) |
| Common Side Effects | Injection reactions (20%), infections (50%), low IgG (declines over time) | Infusion reactions (40%), infections (60%), higher PML risk (rare) |
Kesimpta edges out in convenience for patients avoiding infusions; Ocrevus covers SPMS and may have slightly better disability progression data in some analyses.1
What Do Real-World Studies Show?
Indirect meta-analyses and propensity-matched studies suggest comparable efficacy. A 2023 study of 2,500+ US patients found similar annualized relapse rates (0.15-0.18) and no disability differences after 1 year. Kesimpta showed fewer treatment discontinuations (10% vs 15%) due to easier dosing.4 European registry data (n=1,200) report Ocrevus with marginally better NEDA-3 rates (no relapses, MRI activity, or progression) at 2 years (35% vs 30%), but differences were not statistically significant.5
Which Patients Might Prefer Kesimpta?
Ideal for those prioritizing at-home dosing, needle tolerance, or quicker B-cell knockdown (e.g., highly active RMS). Avoid in primary progressive MS (PPMS), where Ocrevus is approved and superior to placebo (ORATORIO trial).2 Kesimpta's subcutaneous route cuts clinic visits by 80% annually.
Why Might Doctors Choose Ocrevus Instead?
Broader approvals (RMS, active SPMS, PPMS), longer track record (approved 2017 vs Kesimpta's 2020), and strong disability data. Higher raw infection rates but similar adjusted risks; monitor for PML (4 cases per 100,000 patient-years).3
Cost and Access Breakdown
Both list around $65,000-$70,000/year (US wholesale), but copay assistance drops patient costs to $0-$5/month. Ocrevus generics are absent; Kesimpta patents extend to 2031-2035.7 Insurance often favors Ocrevus due to earlier launch.
Ongoing Trials or Patent Challenges?
Phase 4 trials (e.g., ENVISIONS for Kesimpta in SPMS) and switch studies (e.g., Kesimpta post-Ocrevus) are enrolling. No major patent disputes; Novartis (Kesimpta) holds method-of-use patents to 2032, Roche/Genentech (Ocrevus) to 2031.7
Sources